Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®

• Egile Nagusiak: Matthias Balzer (Egilea), Fleur Spiecker (Egilea), Stephanie Bluemel (Egilea), Holger Amthauer (Egilea), Winfried Brenner (Egilea), Sarah Spreckelmeyer (Egilea)
• Formatua: Liburua
• Argitaratua: SpringerOpen, 2023-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background 177Lu-radiopharmaceuticals can contain the metastable impurity [177mLu]lutetium with a physical half-life of 160.4 days, in varying concentrations depending on the route of production of the radionuclidic precursor [177Lu]lutetium. Due to the long half-life of [177mLu]lutetium, d...